Brigatinib in crizotinib-refractory ALK plus non-small cell lung cancer (NSCLC): efficacy updates and exploratory analysis of target lesion response by baseline brain lesion status in the ALTA Trial

D. Kim, R. Huber, M. Ahn, C. Langer, M. Tiseo, H. West, H. Groen, K. Reckamp, M. Hochmair, N. Leighl, K. H. Hansen, S. Gettinger, L. Paz-Ares Rodriguez, E. Kim, E. Smit, S. Kim, W. Reichmann, D. Kerstein, D. R. Camidge

OnderzoeksoutputAcademic

Originele taal-2English
Pagina's (van-tot)S30-S31
Aantal pagina's3
TijdschriftLung Cancer
Volume127
DOI's
StatusPublished - jan.-2019

Citeer dit